Demant stock holds after a 2025 profit rebound
Published on 07/20/2026 at 18:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Demant stock (ISIN DK0010268440) is anchored by a 2025 report year in which the Danish hearing-care group posted DKK 20.3 billion in revenue and DKK 3.4 billion in EBIT before special items. The company also reported DKK 2.0 billion in free cash flow for 2025, showing a business that still converts earnings into cash.
Revenue at DKK 20.3 billion
Revenue reached DKK 20.3 billion in 2025, while EBIT before special items came in at DKK 3.4 billion. That leaves an EBIT margin of about 16.7%, a level that underlines how much the group depends on disciplined pricing and cost control.
The comparison that matters is the shape of the earnings line, not just the top line. Free cash flow of DKK 2.0 billion in 2025 gives the market a second profit-quality marker beyond operating earnings.
Cash flow stayed positive
Demant said free cash flow was DKK 2.0 billion in 2025, a useful counterweight to any single-quarter volatility in hearing-aid demand. A business that produces cash at that scale has more room to fund upgrades in diagnostics, retail, and product launches.
The year also matters because it sets the base for 2026 comparisons. With revenue at DKK 20.3 billion and EBIT before special items at DKK 3.4 billion, investors can judge whether margin expansion continues or stalls.
Hearing aids drive the case
The core product story remains hearing solutions, which is still the clearest business-line lens for Demant. In practical terms, that means the market usually watches whether growth in fitting activity, retail traffic, and device mix supports the reported margin.
That product focus also explains why the companys operating figures matter more than broad company-profile language. The 2025 numbers already show the scale of the franchise: DKK 20.3 billion in revenue, DKK 3.4 billion in EBIT before special items, and DKK 2.0 billion in free cash flow.
Stock level to watch
The article can be read against the 2025 financial base even without a fresh price print in the provided search results. For market context, the relevant figures are still the 2025 revenue, EBIT, and free cash flow, because they frame how any later trading move is priced by the market.
Demant key facts
- Company: Demant A/S
- ISIN: DK0010268440
- Ticker: XETRA: DEMANT
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Health Care Equipment
- Index membership: OMX Copenhagen 25
- Market capitalization: not provided in the available source set
- Next earnings date: not provided in the available source set
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
